Abstract
We assessed the association of postmenopausal serum levels of oestrogens and sex hormone-binding globulin (SHBG) with endometrial cancer risk in a case–control study nested within the NYU Women’s Health Study cohort. Among 7054 women postmenopausal at enrolment, 57 cases of endometrial cancer were diagnosed a median of 5.5 years after blood donation. Each case was compared to 4 controls matched on age, menopausal status at enrolment, and serum storage duration. Endometrial cancer risk increased with higher levels of oestradiol (odds ratio = 2.4 in highest vs lowest tertile, P for trend = 0.02), percent free oestradiol (OR = 3.5, P< 0.001), and oestrone (OR = 3.9, P< 0.001). Risk decreased with higher levels of percent SHBG-bound oestradiol (OR = 0.43, P = 0.03) and SHBG (OR = 0.39, P = 0.01). Trends remained in the same directions after adjusting for height and body mass index. A positive association of body mass index with risk was substantially reduced after adjusting for oestrone level. Our results indicate that risk of endometrial cancer increases with increasing postmenopausal oestrogen levels but do not provide strong support for a role of body mass index independent of its effect on oestrogen levels. © 2001 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Abraham GE, Tulchinsky D and Korenman SG (1970) Chromatographic purification of estradiol 17B for use in radio-ligand assay. Biochem Med 3: 365–368
Aleem FA, Moukhtar MA, Hung HC and Romney SL (1976) Plasma extrogen in patients with endometrial hyperplasia and carcinoma. Cancer 38: 2101–2104
Armstrong B, Whittemore A and Howe G (1989) Analysis of case–control data with covariate measurement error: application to diet and colon cancer. Stat Med 8: 1151–1163
Austin H, Austin JM, Partridge EE, Hatch KD and Shingleton HM (1991) Endometrial cancer, obesity and body fat distribution. Cancer Res 51: 568–572
Benjamin F and Deutsch S (1976) Plasma levels of fractionated estrogens and pituitary hormones in endometrial carcinoma. Am J Obstet Gynecol 126: 638–647
Bremond AG, Claustrat B, Rudigoz RC, Seffert P and Corniau J (1982) Estradiol, androstenedione, testosterone and dehydroepiandrosterone sulfate in the ovarian and peripheral blood of postmenopausal patients with and without endometrial cancer. Gynecol Oncol 14: 119–124
Breslow NE and Day NE (1980). Statistical Methods in Cancer Research volume 1 1, IARC Scientific Publications No. 32: Lyon
Davidson BJ, Gambone JC, Lagasse LD, Castaldo TW, Hammond GL, Sitteri PK and Judd HL (1981) Free estradiol in postmenopausal women with and without endometrial cancer. J Clin Endocrinol Metab 52: 404–408
Derby CA, Lamont Hume A, McFarland Barbour M, McPhillips JB, Lasater TM and Carleton RA (1993) Correlates of postmenopausal estrogen use and trends through the 1980s in two southeastern New England communities. Am J Epidemiol 137: 1125–1135
Ferenczy A, Bertrand G and Gelfand MM (1979) Proliferation kinetics of human endometrium during the normal menstrual cycle. Am J Obstet Gynecol 133: 859–867
Gimes G, Szarvas Z and Siklosi G (1986) Endocrine factors in the etiology of endometrial carcinoma. Neoplasma 33: 393–397
Hankinson SE, Manson JE, Spiegelman D, Willett WC, Longcope C and Speizer F (1995) Reproducibility of plasma hormone levels in postmenopauseal women over a 2–3 year period. Cancer Epidemiol Biomarkers Prev 4: 649–654
Henderson BE, Ross RK, Pike MC and Casagande JT (1982) Endogenous hormones as a major factor in human cancer. Cancer Res 42: 3232–3239
Jasonni VM, Bulletti C, Franceschetti F, Bonavia M, Bolelli G, Ciotti P and Flamigni C (1984) Estrone sulphate plasma levels in postmenopausal women with and without endometrial cancer. Cancer 53: 2698–2700
Judd HL, Lucas WE and Yen SSC (1976) Serum 17β-estradiol and estrone levels in postmenopausal women with and without endometrial cancer. J Clin Endocrinol Metab 43: 272–278
Judd HL, Davidson BJ, Frumar AM, Shamonki IM, Lagasse LD and Ballon SC (1980) Serum androgens and estrogens in postmenopausal women with and without endometrial cancer. Am J Obstet Gynecol 136: 859–871
Kato I, Toniolo P, Koenig K, Kahn A, Schymura M and Zeleniuch-Jacquotte A (1999) Comparison of active and cancer registry-based follow-up for breast cancer in a prospective cohort study. Am J Epidemiol 149: 372–378
Key TJA and Pike MC (1988) The dose-effect relationship between unopposed estrogens and endometrial mitotic rate: Its central role in explaining and predicting endometrial cancer risk. Br J Cancer 57: 205–212
Liang IK and Zeger SL (1986) Longitudinal data analysis using generalized linear models. Biometrika 73: 13–22
Lubin JH and Gail MH (1984) Biased selection of controls for case-control analyses of cohort studies. Biometrics 40: 63–75
Michels KB, Greenland S and Rosner BA (1998) Does body mass index adequately capture the relation of body composition and body size to health outcomes?. Am J Epidemiol 147: 167–172
Mikhail G and Chung HW (1970) Radioimmunoassay of plasma estrogens. Immunologic methods in steroid determination, Peron F Caldwell B (eds) 113, Appleton-Century-Crofts: New York
Nisker JA, Hammond GL, Davidson BJ, Frumar AM, Takaki NK, Judd HL and Siiteri PK (1980) Serum SHBG capacity and the percentage of free estradiol in postmenopausal women with and without endometrial carcinoma. Am J Obstet 138: 637–642
Nyholm HCJ, Nielsen AL, Lyndrup J, Dreisler A, Hagen C and Haug E (1993) Plasma oestrogens in postmenopausal women with endometrial cancer. Br J Obstet Gynaecol 100: 1115–1119
Pettersson B, Bergstrom R and Johansson EDB (1986) Serum estrogens and androgens in women with endometrial carcinoma. Gynecol Oncol 25: 223–233
Pike MC, Peters RK, Cozen W, Probst-Hensch NM, Felix JC, Wan PC and Mack TM (1997) Estrogen-progestin replacement therapy and endometrial cancer. J Natl Cancer Inst 89: 1110–1116
Potischman N, Hoover RN, Brinton LA, Siiteri PK, Dorgan JF, Swanson CA, Berman ML, Mortel R, Twiggs LB, Barrett RJ, Wilbanks GD, Persky V and Lurain JR (1996) Case-control study of endogenous steroid hormones and endometrial cancer. J Natl Cancer Inst 88: 1127–1135
Potischman N, Gail MH, Troisi R, Wacholder S and Hoover RN (1999) Measurement error does not explain the persistence of a body mass index association with endometrial cancer after adjustment for endogenous hormones. Epidemiol 10: 76–79
Sherman ME (2000) Theories of endometrial carcinogenesis: a multidisciplinary approach. Mod Pathol 13: 295–308
Siiteri PK (1978) Steroid hormones and endometrial cancer. Cancer Res 38: 4360–4366
Sonnenschein EG, Kim MY, Pasternack BS and Toniolo P (1993) Sources of variability in waist and hip measurements in middle- aged women. Am J Epidemiol 138: 301–309
Toniolo PG, Pasternack BS, Shore RE, Sonnenschein EG, Koenig KL, Rosenberg C, Strax P and Strax S (1991) Endogenous hormones and breast cancer: a prospective cohort study. Breast Cancer Res Treat 18: S23–S26
Toniolo P, Koenig KL, Pasternack BS, Banerjee S, Rosenberg C, Shore RE, Strax P and Levitz M (1994) Reliability of measurements of total, protein-bound, and unbound estradiol in serum. Cancer Epidemiol Biomarkers Prev 3: 47–50
Toniolo P, Levitz M, Zeleniuch-Jacquotte A, Banerjee S, Koenig KL, Shore RE, Strax P and Pasternack BS (1995) A prospective study of endogenous estrogens and breast cancer in postmenopausal women. J Natl Cancer Inst 87: 190–197
von Holst T, Klinga K and Runnebaum B (1981) Hormone levels in healthy postmenopausal women and women with postmenopausal bleeding with and without endometrial carcinoma. Maturitas 3: 315–320
Weiderpass E, Adami H, Baron J, Magnusson C, Bergstrom R, Lindgren A, Correia N and Persson I (1999) Risk of endometrial cancer following estrogen replacement with and without progestins. J Natl Cancer Inst 91: 1131–1137
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Zeleniuch-Jacquotte, A., Akhmedkhanov, A., Kato, I. et al. Postmenopausal endogenous oestrogens and risk of endometrial cancer: results of a prospective study. Br J Cancer 84, 975–981 (2001). https://doi.org/10.1054/bjoc.2001.1704
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1054/bjoc.2001.1704
Keywords
This article is cited by
-
Endometrial hyperplasia as a risk factor of endometrial cancer
Archives of Gynecology and Obstetrics (2022)
-
Testosterone, sex hormone-binding globulin, insulin-like growth factor-1 and endometrial cancer risk: observational and Mendelian randomization analyses
British Journal of Cancer (2021)
-
Oral contraceptive use by formulation and endometrial cancer risk among women born in 1947–1964: The Nurses’ Health Study II, a prospective cohort study
European Journal of Epidemiology (2021)
-
Case–control study of endogenous sex steroid hormones and risk of endometrial cancer
Cancer Causes & Control (2020)
-
Circulating estrogens and postmenopausal ovarian and endometrial cancer risk among current hormone users in the Women’s Health Initiative Observational Study
Cancer Causes & Control (2019)
